Revealing Angiopep-2/LRP1 Molecular Interaction for Optimal Delivery to Glioblastoma (GBM)

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Oct 14

PMID 36235232

Authors

Angela Costagliola di Polidoro

Andrea Cafarchio

Donatella Vecchione

Paola Donato

Francesco De Nola

Enza Torino

Affiliations

Soon will be listed here.

Abstract

Background: The family of synthetic peptide angiopeps, and particularly angiopep-2 (ANG-2) demonstrated the ability preclinically and clinically to shuttle active molecules across the blood-brain barrier (BBB) and selectively toward brain tumor cells. The literature has also proved that the transport occurs through a specific receptor-mediated transcytosis of the peptide by LRP-1 receptors present both on BBB and tumor cell membranes. However, contradictory results about exploiting this promising mechanism to engineer complex delivery systems, such as nanoparticles, are being obtained.

Methodology: For this reason, we applied a molecular docking (MD)-based strategy to investigate the molecular interaction of ANG-2 and the LRP-1 ligand-binding moieties (CR56 and CR17), clarifying the impact of peptide conjugation on its transport mechanism.

Results: MD results proved that ANG-2/LRP-1 binding involves the majority of ANG-2 residues, is characterized by high binding energies, and that it is site-specific for CR56 where the binding to 929ASP recalls a transcytosis mechanism, resembling the binding of the receptor to the receptor-associated protein. On the other hand, ANG-2 binding to CR17 is less site-specific but, as proved for apolipoprotein internalization in physiological conditions, it involves the ANG-2 lysin residue.

Conclusions: Overall, our results proved that ANG-2 energetic interaction with the LRP-1 receptor is not hindered if specific residues of the peptide are chemically crosslinked to simple or complex engineered delivery systems.

Citing Articles

Targeting GDF15 to enhance immunotherapy efficacy in glioblastoma through tumor microenvironment-responsive CRISPR-Cas9 nanoparticles.

Zou C, Liu X, Wang W, He L, Yin A, Cao Z J Nanobiotechnology. 2025; 23(1):126.

PMID: 39979966 PMC: 11843742. DOI: 10.1186/s12951-025-03182-8.

Advancements in nanotheranostics for glioma therapy.

Sahoo L, Paikray S, Tripathy N, Fernandes D, Dilnawaz F Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39480526 DOI: 10.1007/s00210-024-03559-w.

The multifaceted therapeutical role of low-density lipoprotein receptor family in high-grade glioma.

Mastrantuono E, Ghibaudi M, Matias D, Battaglia G Mol Oncol. 2024; 18(12):2966-2976.

PMID: 39276062 PMC: 11619799. DOI: 10.1002/1878-0261.13730.

References

Regina A, Demeule M, Che C, Lavallee I, Poirier J, Gabathuler R . Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008; 155(2):185-97. PMC: 2538693. DOI: 10.1038/bjp.2008.260. View

Guttman M, Prieto J, Handel T, Domaille P, Komives E . Structure of the minimal interface between ApoE and LRP. J Mol Biol. 2010; 398(2):306-19. PMC: 2880916. DOI: 10.1016/j.jmb.2010.03.022. View

Xin H, Sha X, Jiang X, Chen L, Law K, Gu J . The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles. Biomaterials. 2011; 33(5):1673-81. DOI: 10.1016/j.biomaterials.2011.11.018. View

Lamiable A, Thevenet P, Rey J, Vavrusa M, Derreumaux P, Tuffery P . PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Res. 2016; 44(W1):W449-54. PMC: 4987898. DOI: 10.1093/nar/gkw329. View

Jensen G, Andersen O, Bonvin A, Bjerrum-Bohr I, Etzerodt M, Thogersen H . Binding site structure of one LRP-RAP complex: implications for a common ligand-receptor binding motif. J Mol Biol. 2006; 362(4):700-16. DOI: 10.1016/j.jmb.2006.07.013. View

Meng X, Zhang H, Mezei M, Cui M . Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011; 7(2):146-57. PMC: 3151162. DOI: 10.2174/157340911795677602. View

Pucci C, De Pasquale D, Marino A, Martinelli C, Lauciello S, Ciofani G . Hybrid Magnetic Nanovectors Promote Selective Glioblastoma Cell Death through a Combined Effect of Lysosomal Membrane Permeabilization and Chemotherapy. ACS Appl Mater Interfaces. 2020; 12(26):29037-29055. PMC: 7343532. DOI: 10.1021/acsami.0c05556. View

Lu C, Zhao Y, Wong H, Cai J, Peng L, Tian X . Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine. 2014; 9:2241-57. PMC: 4026551. DOI: 10.2147/IJN.S61288. View

Barar J, Rafi M, Pourseif M, Omidi Y . Blood-brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2017; 6(4):225-248. PMC: 5326671. DOI: 10.15171/bi.2016.30. View

10.

Bertrand Y, Currie J, Demeule M, Regina A, Che C, Abulrob A . Transport characteristics of a novel peptide platform for CNS therapeutics. J Cell Mol Med. 2009; 14(12):2827-39. PMC: 3822732. DOI: 10.1111/j.1582-4934.2009.00930.x. View

11.

Kumthekar P, Tang S, Brenner A, Kesari S, Piccioni D, Anders C . ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020; 26(12):2789-2799. DOI: 10.1158/1078-0432.CCR-19-3258. View

12.

Costagliola di Polidoro A, Zambito G, Haeck J, Mezzanotte L, Lamfers M, Netti P . Theranostic Design of Angiopep-2 Conjugated Hyaluronic Acid Nanoparticles (Thera-ANG-cHANPs) for Dual Targeting and Boosted Imaging of Glioma Cells. Cancers (Basel). 2021; 13(3). PMC: 7865309. DOI: 10.3390/cancers13030503. View

13.

Li Y, Zheng X, Gong M, Zhang J . Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma. Oncotarget. 2016; 7(48):79401-79407. PMC: 5346723. DOI: 10.18632/oncotarget.12708. View

14.

Lee D, Walsh J, Migliorini M, Yu P, Cai T, Schwieters C . The structure of receptor-associated protein (RAP). Protein Sci. 2007; 16(8):1628-40. PMC: 2203372. DOI: 10.1110/ps.072865407. View

15.

Pitas R, Innerarity T, Mahley R . Cell surface receptor binding of phospholipid . protein complexes containing different ratios of receptor-active and -inactive E apoprotein. J Biol Chem. 1980; 255(11):5454-60. View

16.

Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X . Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials. 2012; 33(32):8167-76. DOI: 10.1016/j.biomaterials.2012.07.046. View

17.

van Rooy I, Mastrobattista E, Storm G, Hennink W, Schiffelers R . Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release. 2010; 150(1):30-6. DOI: 10.1016/j.jconrel.2010.11.014. View

18.

Wang H, Eckel R . What are lipoproteins doing in the brain?. Trends Endocrinol Metab. 2013; 25(1):8-14. PMC: 4062975. DOI: 10.1016/j.tem.2013.10.003. View

19.

Beaufays J, Lins L, Thomas A, Brasseur R . In silico predictions of 3D structures of linear and cyclic peptides with natural and non-proteinogenic residues. J Pept Sci. 2011; 18(1):17-24. DOI: 10.1002/psc.1410. View

20.

Liu B, Zhang Z, Lu S, He Q, Deng N, Meng H . In-silico analysis of ligand-receptor binding patterns of α-MMC, TCS and MAP30 protein to LRP1 receptor. J Mol Graph Model. 2020; 98:107619. DOI: 10.1016/j.jmgm.2020.107619. View